Linked Data API

Show Search Form

Search Results

1134018
star this property registered interest false more like this
star this property date less than 2019-06-24more like thismore than 2019-06-24
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Accelerated Access Collaborative more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, if he will list the (a) criteria and (b) timelines for products to be considered in (i) the current round and (ii) future review rounds of the Accelerated Access Collaborative route. more like this
star this property tabling member constituency Strangford more like this
star this property tabling member printed
Jim Shannon remove filter
star this property uin 268506 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-07-02more like thismore than 2019-07-02
star this property answer text <p>In October 2018, the Accelerated Access Collaborative (AAC) announced it was supporting the uptake of 12 high performing products, with the potential to improve the lives of up to 500,000 patients per year and save the National Health Service £30 million per year in England. All the products currently being supported by the AAC have been recommended by the National Institute for Health and Care Excellence, and therefore evidence on clinical benefits and cost savings were considered as part of the process.</p><p>The AAC board met on 26 June and had a positive discussion about future products and expects to announce further products later this year.</p><p>The AAC will consider the following areas of interest when determining which products to support:</p><p>- evidence of clinical and cost effectiveness;</p><p>- addressing significant unmet need;</p><p>- application to large populations or high budget impact; and</p><p>- enabling a novel mode of action or enabling significant changes to the care pathway.</p><p> </p><p> </p>
star this property answering member constituency Gosport more like this
star this property answering member printed Caroline Dinenage remove filter
star this property question first answered
remove filter
star this property answering member
4008
star this property label Biography information for Caroline Dinenage more like this
star this property tabling member
4131
unstar this property label Biography information for Jim Shannon more like this